scispace - formally typeset
Open AccessJournal ArticleDOI

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

About
This article is published in Journal of the American College of Cardiology.The article was published on 2019-06-25 and is currently open access. It has received 1309 citations till now.

read more

Citations
More filters
Journal ArticleDOI

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary

TL;DR: Grundy et al. as discussed by the authors proposed Grundy, MD, PhD, FAHA, Chair, Writing Committee, Neil J. Stone, MD and Alison L. Bailey, MD MD, FACC, FAACVPR, writing committee member, Craig Beam, CRE, Writing committee Member, Kim K. Birtcher, MS, PharmD, AACC, FNLA, writing Committee Member, Roger S. Blumenthal, MD.
Journal ArticleDOI

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

TL;DR: In this paper, the authors proposed a method to solve the problem of the problem: this paper ] of "uniformity" of the distribution of data points in the data set.
References
More filters
Journal ArticleDOI

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

TL;DR: In this paper, the authors compared a lifestyle intervention with metformin to prevent or delay the development of Type 2 diabetes in nondiabetic individuals. And they found that the lifestyle intervention was significantly more effective than the medication.
Journal ArticleDOI

Prediction of Coronary Heart Disease Using Risk Factor Categories

TL;DR: A simple coronary disease prediction algorithm was developed using categorical variables, which allows physicians to predict multivariate CHD risk in patients without overt CHD.
Journal ArticleDOI

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

TL;DR: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.
Related Papers (5)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

François Mach, +120 more